BERTON GIACHETTI, PIER PAOLO MARIA
BERTON GIACHETTI, PIER PAOLO MARIA
Universita' degli Studi di MILANO
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
2025 P. Zagami, A. Esposito, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, R. Scafetta, M. Lambertini, M. Di Maio, G. Curigliano, C. Criscitiello, S. Cinieri
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
2025 K. Venetis, G. Cursano, R. Scafetta, P.P.M.B. Giachetti, A. Concardi, E. De Camilli, M. D'Ercole, E. Mane, C. Frascarelli, A. Marra, S. Gandini, F. Pepe, S. Scagnoli, S.M. Rossi, R. Troiano, E. Speziale, C. De Angelis, G. Troncone, U. Malapelle, G. Perrone, A. Botticelli, G. Viale, G. Curigliano, E. Guerini Rocco, C. Criscitiello, N. Fusco
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
2025 B. Taurelli Salimbeni, F. Giudici, C. Pescia, P.P.M. Berton Giachetti, R. Scafetta, P. Zagami, A. Marra, D. Trapani, A. Esposito, S. Scagnoli, B. Cerbelli, A. Botticelli, E. Munzone, N. Fusco, C. Criscitiello, G. Curigliano
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
PARP Inhibitors for Breast Cancer Treatment
2024 S. Morganti, A. Marra, C. De Angelis, A. Toss, L. Licata, F. Giugliano, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, A. Esposito, A. Giordano, G. Bianchini, E. Garber Judy, G. Curigliano, F. Lynce, C. Criscitiello
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study
2023 S. Morganti, A. Marra, S. Gandini, L. Ascione, M. Ivanova, K. Venetis, E. Sajjadi, P. Zagami, F. Giugliano, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, C. Corti, E. De Camilli, G. Curigliano, N. Fusco, C. Criscitiello
Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection
2023 D. Trapani, J. Sandoval, P.T. Aliaga, L. Ascione, P.P. Maria Berton Giachetti, G. Curigliano, O. Ginsburg
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations
2021 E. Nicolò, D. Trapani, P.P.M. Berton Giachetti, P. Zagami, G. Curigliano